Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors.

Trial Profile

Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Contusugene ladenovec (Primary) ; Carboplatin; Fluorouracil; Methotrexate
  • Indications Orofacial cancer
  • Focus Therapeutic Use
  • Sponsors Shenzhen SiBiono GeneTech
  • Most Recent Events

    • 31 May 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2013 Status changed from recruiting to active, no longer recruiting.
    • 09 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top